At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 50 target
Drug / intervention
Fecal microbiota suspensiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Fecal Microbiota Transplantation for Epilepsy
The Second Hospital of Nanjing Medical University·interventional·Posted Sep 5, 2016·Updated Mar 20, 2024
In Brief
A Phase 3 clinical trial evaluating Fecal microbiota suspension for Epilepsy. Targeting 50 participants across 1 site.
Detailed Summary
Increasing evidences showed the microbiota effects on neuropsychiatric disorders. This clinical trial aims to evaluate the efficacy and safety of fecal microbiota transplantation for epilepsy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
CountriesChina
Collaborators--
Timeline
Phase 3UnknownOverdue
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionOct 2025
Study CompletionDec 2025
TodayJul 2026
First PostedSep 5, 2016
Enrollment StartNov 1, 2016
Primary CompletionOct 1, 2025
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 8.9 yearsPosted 9.8 years ago
Interventions
Fecal microbiota suspensiondrug
The prepared microbiota suspension was infused into the participates' mid-gut or lower gut.